Stockscreener 앱 받기
48.25
1.75%
-0.86
시간 외 거래:
48.94
0.69
+1.43%
전일 마감가:
$49.11
열려 있는:
$47.96
하루 거래량:
28.37M
Relative Volume:
1.87
시가총액:
$163.57B
수익:
$45.45B
순이익/손실:
$16.18B
주가수익비율:
13.29
EPS:
3.6297
순현금흐름:
$8.96B
1주 성능:
-7.30%
1개월 성능:
-19.08%
6개월 성능:
-30.30%
1년 성능:
-56.02%
1일 변동 폭
$47.76
$49.90
1주일 범위
$47.76
$52.80
52주 변동 폭
$45.05
$112.52
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.25 | 218.22B | 45.45B | 16.18B | 8.96B | 3.6297 |
|
LLY
Lilly Eli Co
|
906.86 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.89 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Should You Buy Novo Nordisk Stock Before the Huge Investor Update? - The Motley Fool
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
P/E Ratio Insights for Novo Nordisk - Sahm
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk Stock Is Falling Friday: What's Driving The Action? - Sahm
What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem - Sahm
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm
Novo Nordisk layoffs: Pharma major begins job cuts in US amid fierce weight-loss drug battle — Here's what we know - livemint.com
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm
Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations - Sahm
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm
UBS Sticks to Their Hold Rating for Novo Nordisk (0QIU) - The Globe and Mail
BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail
J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - sharewise.com
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa
Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent
NVO Stock Quote Price and Forecast - CNN
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.13%
1.46%
자본화:
|
볼륨(24시간):